ACE Reno for Chronic Kidney Disease
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
Recruiting
Phase 4
Interventional Study
Hypertensive Nephropathy
Auto Immune Disorders
Chronic Kidney Disease
Chronc Kidney Disease Stage 5
Chronic Kidney Disease (Stage 3-4)
Chronic Kidney Disease (Stages 4 and 5)
Microalbuminuria
Diabetic Nephropathies
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 300 (estimated)
- Sponsor
- Ace Cells Lab Limited · Industry
Who this trial is looking for
This trial is looking for adults with kidney problems like nephropathy. Participants will take ACE Reno, a medication, under the tongue for 12 weeks to see if it helps improve kidney function and reduce protein in urine.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I have nephropathy or chronic kidney disease.
- I have protein in my urine.
- I am not on dialysis.
- I have stable background therapy with ACEi, ARB, SGLT2i, or MRA.
You may not be able to join if
- I had a kidney transplant in the last 12 months.
- I have an uncontrolled acute infection.
- I have an unstable autoimmune disease.
- I am pregnant or breastfeeding.
- I am allergic to any study components.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria/proteinuria and stabilizes kidney function in participants with nephropathy due …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years) with nephropathy of any degree (microalbuminuria, overt proteinuria, CKD stages 1-5 not on dialysis, or post-transplant with proteinuria). Stable background therapy with ACEi/ARB, SGLT2i, or MRA allowed.
Exclusion Criteria:
* Recent kidney transplant (\<12…
Contacts